Chronic Kidney Disease Registry Platform Study

Exclusion Criteria

• •1. Patients who have previously undergone/are undergoing/are planning to undergo solid organ transplantation;
• •2. Patients with active malignant tumor requiring drug therapy at the time of screening;
• •3. Women who are pregnant, planning to become pregnant or who are breastfeeding.
• •1. Patients with NYHA class III or IV heart failure at screening;
• •2. Patients who have had myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), or undergone cardiac surgery, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), valvular repair/replacement, or received treatment with left ventricular assist device within 3 months prior to screening;
• •3. Patients undergoing renal replacement therapy (RRT) at screening;
• •4. Patients on systemic immunosuppression at screening (inhalation, intranasal administration, or topical steroids are allowed) except for stable maintenance therapy. The stable maintenance therapy means treatment at least 3 months with Prednisone 10mg/day or lower (or equivalent dose of other drugs), Azathioprine 100mg/day or lower, or Mycophenolate mofetil 1000mg/day or lower (or equivalent dose of other drugs);
• •5. Patients with a life expectancy of less than 1 year, as judged by the investigator;
• •6. Patients who have participated in another interventional clinical trial and have received the investigational drug within 1 month prior to being enrolled.
• •1. Patients with NYHA class IV heart failure at screening;
• •2. Patients who have had stroke, transient ischemic attack (TIA), Carotid artery surgery or carotid angioplasty and stenting, acute Coronary Syndrome, or hospitalization caused by heart failure deterioration within 3 months prior to screening;
• •3. Patients who have known severe hepatic injury (defined as Child-Pugh class C) based on medical history;
• •4. Patients undergoing renal replacement therapy (RRT) within 12 weeks prior to screening;
• •5. Patients on systemic immunosuppression prior to screening (inhalation, intranasal administration, or topical steroids are allowed) except for stable maintenance therapy at least 3 months;
• •6. Patients with a life expectancy of less than 1 year, as judged by the investigator;
• •7. Patients who have participated in another interventional clinical trial and have received the investigational drug within 1 months prior to being enrolled.